“…In patients with atherosclerotic RAS, procedural efficacy of PTRA is estimated at 72-92% [15,16] , while restenosis in 6-to 9-month follow-up is noted as often as in 10-30% of cases [16,17] . In the case of ostial lesions, outcomes are worse; procedural efficacy is only 10-40% [18] , or according to other authors 57-62% [17] , with the 6-month restenosis rate reaching 25-50% [19] .…”